Alera Pharma Launches with Neurology Focus and New Leadership
Alera Pharma, a Lobe Sciences unit, focuses on neurology with new assets and key leadership.
Alera Pharma, a fully owned US subsidiary of
biopharmaceutical business Lobe Sciences, was established to create solutions
for unmet medical needs. Psilocin Mucate, the company's new chemical entity,
and its neurological assets will fall under the intellectual property rights of
Alera. Alera's CEO will be Rick Goulburn, and its board of directors chairman
will be Dr. Fred D. Sancilio.
Alera will operate as the neurology-focused operating firm
under Lobe Sciences and will become the second operational subsidiary alongside
Altemia, LLC. It is anticipated that Lobe Sciences Australia Pty Ltd., the
Australian subsidiary, would merge with Alera. Ilan Hayman will become a member
of Alera's senior management group. Dr. Sancilio stressed that Lobe Sciences'
activities have been reduced to three organisations, with Lobe Sciences
providing common services to the two operating subsidiaries.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Novo Nordisk firma un acuerdo de $2.6B con Hengrui por un GLP-1 oral
Discussion